Vilon

Vilon is the KE dipeptide, Lys-Glu. It has several PubMed-indexed preclinical and in vitro papers, but still lacks modern regulatory-grade human evidence. In mouse splenocytes, Vilon activated interleukin-2 mRNA synthesis in vitro. Animal studies reported effects on spontaneous tumor incidence and lifespan in mice and chemically induced urinary bladder carcinogenesis in rats; these are preclinical oncology and aging models, not treatment claims. A 2023 human mesenchymal stem-cell aging study examined KE effects on SIRT1 and PARP-family gene and protein expression. Vilon should be described as an experimental immunomodulatory and gerontology peptide with gene-expression and animal-model signals.

Immune Signaling

Vilon activated IL-2 mRNA synthesis in mouse splenocytes in vitro, with effects dependent on peptide type, concentration, and exposure time ^[1].

Aging and Cell Models

Animal tumor/lifespan studies and human mesenchymal stem-cell aging cultures support research interest in KE-related gene-expression and aging biology ^[2][4].

Evidence Boundary

Animal tumor findings are not evidence of clinical anticancer efficacy or human longevity benefit ^[2][3].

Missing Modern Safety Data

Vilon lacks modern human phase 1, dosing, pharmacokinetic, and long-term safety evidence ^[1][4].

Immune and Gene-Expression Caution

Immune and gene-expression activity creates theoretical risk in autoimmune disease, malignancy, immunosuppression, pregnancy, and inflammatory disorders, but these risks are not quantified ^[1][4].